Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIVEN: Pexidartinib in Tenosynovial Giant Cell Tumor
NCT02371369Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2015
- Primary completion
- Mar 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 12
01
Overview
A Phase 3 trial of pexidartinib in tenosynovial giant cell tumor (TGCT), sponsored by Daiichi Sankyo Co., Ltd.. Started May 2015; status: completed.
02
Drugs
pexidartinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT02371369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02371369.